B-cell-specific signatures reveal novel immunophenotyping and therapeutic targets for hepatocellular carcinoma  

作　　者：Ke-Quan Xu Zheng Gong Jia-Ling Yang Chu-Qi Xia Jian-Yi Zhao Xi Chen 

机构地区：[1]Department of Hepatobiliary and Pancreatic Surgery,Zhongnan Hospital of Wuhan University,Wuhan 430071,Hubei Province,China [2]Department of Pharmacy,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,Hubei Province,China [3]School of Basic Medical Sciences,Nanjing Medical University,Nanjing 211166,Jiangsu Province,China [4]Department of Gastrointestinal Surgery,The Second Affiliated Hospital of Kunming Medical University,Kunming 650101,Yunnan Province,China [5]Department of General Surgery,Second People’s Hospital of Jiaozuo City,Jiaozuo 454001,Henan Province,China

出　　处：《World Journal of Gastroenterology》2024年第34期3894-3925,共32页世界胃肠病学杂志（英文版）

基　　金：Supported by the Fundamental Research Funds for the Central Universities(2042024YXB009 to X.C.);Special Foundation for knowledge innovation of Wuhan Science and Technology Innovation Bureau(2023020201020510 to X.C.).

摘　　要：BACKGROUND Immunotherapy presents both promises and challenges in treating hepatocellular carcinoma(HCC)due to its complex immunological microenvironment.The role of B cells,a key part of the immune system,remains uncertain in HCC.AIM To identify B-cell-specific signatures and reveal novel immunophenotyping and therapeutic targets for HCC.METHODS Using the Tumor Immune Single-cell Hub 2 database,we identified B-cell-related genes(BRGs)in HCC.Gene enrichment analysis was performed to explore the possible collaboration between B cells and T cells in HCC.We conducted univariate Cox regression analysis using The Cancer Genome Atlas liver HCC collection dataset to find BRGs linked to HCC prognosis.Subsequently,least absolute shrinkage and selection operator regression was utilized to develop a prognostic model with 11 BRGs.The model was validated using the International Cancer Genome Consortium dataset and GSE76427.RESULTS The risk score derived from the prognostic model emerged as an independent prognostic factor for HCC.Analysis of the immune microenvironment and cell infiltration revealed the immune status of various risk groups,supporting the cooperation of B and T cells in suppressing HCC.The BRGs model identified new molecular subtypes of HCC,each with distinct immune characteristics.Drug sensitivity analysis identified targeted drugs effective for each HCC subtype,enabling precision therapy and guiding clinical decisions.CONCLUSION We clarified the role of B cells in HCC and propose that the BRGs model offers promising targets for personalized immunotherapy.

关 键 词：B cell Hepatocellular carcinoma Immune microenvironment IMMUNOTHERAPY Molecular subtype 

分 类 号：R735.7[医药卫生—肿瘤]